Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL-050
- Development stage
- Unknown
- Lead developer
- Shenzhen Qinglan Biotechnology
- Modality
- Peptides
- Administration
- Transdermal
01
Overview
QL-050 is a dual glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist peptide developed by BioQingLam. It is formulated as a transdermal soluble microneedle patch, utilizing the company's proprietary drug delivery platform. The drug is currently in Phase III clinical development for the treatment of Type 2 Diabetes Mellitus (T2DM) and obesity. By targeting both GLP-1 and GIP receptors, QL-050 aims to improve glycemic control and promote weight loss with the convenience of a needle-free, transdermal application. The development follows a 505(b)(2) or hybrid innovation pathway, focusing on accelerated clinical progress.
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on QL-050.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL-050.